摘要
2019年12月暴发的新型冠状病毒肺炎(COVID-19)传染性强,给人类社会带来巨大威胁和损失,引起各国政府高度重视。目前,针对COVID-19尚无特效药物,多种可能有效的抗病毒药物、疫苗、细胞治疗、中药治疗等方法正在进行临床试验。肝损伤是COVID-19患者治疗过程中常见的并发症,发生率较高,且能够影响疾病转归。当前研究中COVID-19合并肝损伤发生机制尚不明确,临床诊断及治疗缺乏相关指南和专家共识,现将相关进展和问题进行综述。
The highly contagious novel coronavirus pneumonia(COVID-19)that broke out in December 2019 has brought huge threats and losses to human society,so it has been the concern of every countries government.Presently,there are no specific drugs for COVID-19;however,a variety of potentially effective antiviral drugs,vaccines,cell therapies,traditional Chinese medicine and other methods are in clinical trials.Liver injury is a common complication of patients receiving COVID-19 treatment and its possible high incidence may affect the outcome of the disease.The pathogenesis of COVID-19 combined with liver injury in existing studies is still unclear,and relevant guidelines and expert consensuses are insufficient for clinical diagnosis and treatment.Therefore,the relevant progress and issues are now reviewed here.
作者
谢云波
王嗣予
张超
王福生
Xie Yunbo;Wang Siyu;Zhang Chao;Wang Fusheng(Medical School of Chinese PLA,Beijing 100853,China;Treatment and Research Center of Infectious Diseases,The Fifth Medical Center of PLA General Hospital,Beijing 100039,China)
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2020年第6期523-527,共5页
Chinese Journal of Hepatology
关键词
新型冠状病毒肺炎
新型冠状病毒
肝损伤
COVID-19
SARS-CoV-2(Severe Acute Respiratory Syndrome Voronavirus 2)
Liver injury
